• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Daiichi Sankyo to distribute Penthrox methoxyflurane inhaler in China

According to Medical Developments International (MVP), Daiichi Sankyo will pay up to $32.5 million for the rights to distribute MVP’s Penthrox methoxyflurane inhaler in China, Vietnam, and Thailand. The deal includes $15 million up front plus sales milestones.

MVP will pay up to $10 million toward acquiring marketing approval in China, will own the drug import license after approval, and will retain the intellectual property from the Chinese development process. Both companies will work with Japanese company EPS International Holdings, which provides clinical and regulatory services.

Penthrox is currently approved in Australia, Canada, and most of Europe. The US clinical development program for Penthrox is currently on a clinical hold; MVP recently announced that it believes that it can meet the requirements specified by the FDA in the clinical hold letter.

MVP CEO John Sharman commented, “We are delighted to partner with Daiichi Sankyo, one of Japan’s biggest pharmaceutical companies. Daiichi Sankyo shares our vision for the potential of Penthrox in China, Thailand and Vietnam. Acute pain in trauma and minor surgical procedures is undertreated in the Chinese healthcare system. MVP believes there is an important place for Penthrox in pain management in China. Penthrox, with its fact acting, non-addictive, non-opioid characteristics will be an important tool for pain management in the Chinese, Vietnamese and Thai markets.”

Read the MVP press release.

Share

published on October 8, 2018

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews